Instructions for Niatira (rifamycin) ear drops
ATX code: S02AA12 (Rifamycin)
Active ingredient:
rifamycin (rifamycin)
Rec.INN registered by WHO
Drug form Niatira
Niatira®
Ear drops 2.6%
reg. No. : LP-(000935)-(WP-RU) from 24.06.22 - Current
The form of release, packaging and composition of the drug Niatira®
Ear drops
Rifamytsin 2.6%
10 ml - vials
Pharmacological effect Niatira
The antibiotic rifampicin, belonging to the rifamycin group, was derived from the radiant fungus Streptomyces mediterranei and has the ability to inhibit RNA synthesis by forming a complex with DNA-dependent RNA polymerase. This drug has a bactericidal effect.
In low concentrations, it is active against microorganisms such as Mycobacterium tuberculosis, Staphylococcus spp., Streptococcus spp. (including Streptococcus pneumoniae), Neisseria gonorrhoeae, Neisseria meningitidis. At higher concentrations, rifampin is active against Escherichia coli, Proteus spp.
Notably, this antibiotic is active against strains of microorganisms resistant to semisynthetic penicillins and cephalosporins. It is also important to note that rifampin does not interact with other antibiotics other than its own antibiotic.
Pharmacokinetics Niatira
When injected into a muscle, rifampin is absorbed rapidly, peaking in 30 minutes. The therapeutic level of this drug is maintained for 6 to 8 hours. A four-fold increase in peak concentration results in a 1.5- to 3-fold increase in peak concentration; IV concentration becomes higher but decreases more rapidly. Rifampin does not accumulate in the body.
Plasma protein binding is 60 to 70%. Distribution of rifampin occurs maximally in the liver and to a lesser extent in the kidneys, lungs, and ascitic and pleural fluids. The drug is retained in the foci of inflammation for a long time. It does not cross the blood-brain barrier but can cross the placental barrier. Rifampin is metabolized to form an active metabolite. The drug is half-metabolized in the body in 2 hours. It is excreted in bile (in volume 60 to 90% over 8 to 24 hours) and, in small amounts, urine. The intestine partially reabsorbs rifampin, allowing it to circulate for a long time. Also, if bile flow is disrupted, plasma levels increase.
When used topically as ear drops, rifampin has a low degree of absorption into the systemic circulation.
Indications of active substances of Niatir Niatira®
Infectious and inflammatory diseases due to rifamycin-sensitive organisms, including gonorrhea, tuberculosis.
- ICD-10 Code Indication
- A15 Tuberculosis of respiratory organs, confirmed by bacterial and histological culture
- A17 Tuberculosis of nervous system
- A18 Tuberculosis of other organs
- A54 Gonococcal infection
Dosing mode Niatira
The mode of administration and dosage of the drug will be determined by its form of release and other factors, and the doctor will determine the optimal dosage regime. It is important to strictly follow the dosage form, indications, and dosing regimen.
For adults and children over age 6 who weigh more than 25 kg, an IM dose of 500 to 750 mg every 8 and 12 hours is recommended. For children up to 6 years of age, the dosage is 125 mg every 12 hours.
The following dosage is recommended when the preparation is injected intravenously: for adults and children weighing more than 25 kg - 500 mg per day, for children weighing less than 25 kg - the daily dose is 10-30 mg per kilogram of body weight, with a dosage of 2-4 times a day.
For ear diseases in adults and children, topical twice-daily therapy is used.